Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Atomo Diagnostics Ltd. ( (AU:AT1) ).
Atomo Diagnostics has issued a target market determination for unlisted options attached to a security purchase plan and related shortfall offer, giving eligible Australian and New Zealand shareholders the right to acquire new shares at $0.033 with free options exercisable at $0.045 over 2.5 years. The company frames the offer as suitable for investors comfortable with speculative, illiquid options in a small/mid-cap healthcare stock who can commit capital over the medium term and tolerate volatility, while stressing that the options will not be quoted on the ASX, offer no guaranteed returns, and require investors to fund any future exercise themselves.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian small to mid-cap healthcare and equipment services company listed on the ASX, focused on providing diagnostic solutions. Its securities attract investors seeking exposure to speculative healthcare equities rather than immediate income or capital protection.
Average Trading Volume: 2,349,202
Technical Sentiment Signal: Hold
Current Market Cap: A$25.23M
See more insights into AT1 stock on TipRanks’ Stock Analysis page.